Friedreich's ataxia: Past, present and future

Brain Research Reviews

Volumn 67, Issue 1-2, 2011, Pages 311-330

  Marmolino, Daniele ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Fe S cluster; Frataxin; Friedreich's ataxia; GAA; Iron; Oxidative stress

Indexed keywords

ALPHA TOCOPHEROL; BML 210; CATENA; CELL NUCLEUS DNA; DEFERIPRONE; DEFEROXAMINE; EPI A 000 1; EPI A 0001; FERREDOXIN; FRATAXIN; HISTONE DEACETYLASE INHIBITOR; HYBRID PROTEIN; IDEBENONE; IRON SULFUR PROTEIN; MITOCHONDRIAL DNA; N1 (2 AMINOPHENYL) N7 4 TOLYLHEPTANEDIAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLACEBO; RECOMBINANT ERYTHROPOIETIN; SCAFFOLD PROTEIN; SCAFFOLD PROTEIN ISCU; TRANSACTIVATOR OF TRANSCRIPTION FRATAXIN FUSION PROTEIN; UBIDECARENONE; UBIQUINONE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; AREFLEXIA; CLINICAL FEATURE; DIABETES MELLITUS; DYSARTHRIA; EYE MOVEMENT DISORDER; FOOT MALFORMATION; FRIEDREICH ATAXIA; FXN GENE; GENE CLUSTER; GENOTYPE PHENOTYPE CORRELATION; HEARING LOSS; HEART DISEASE; HUMAN; IRON BINDING CAPACITY; IRON CHELATION; IRON METABOLISM; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PATHOPHYSIOLOGY; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SCOLIOSIS; SENSORY DYSFUNCTION; SPINAL CORD ATROPHY; TRINUCLEOTIDE REPEAT; VIBRATION SENSE; VISUAL IMPAIRMENT;

ANIMALS; DRUG DESIGN; FRIEDREICH ATAXIA; HUMANS; IRON METABOLISM DISORDERS; IRON-BINDING PROTEINS; MITOCHONDRIAL DISEASES; PROGNOSIS;

EID: 79957959532     PISSN: 01650173     EISSN: 18726321     Source Type: Journal    
DOI: 10.1016/j.brainresrev.2011.04.001     Document Type: Review

References (191)

1. Acquaviva F., De Biase I., Nezi L., et al. Extra-mitochondrial localisation of frataxin and its association with IscU1 during enterocyte-like differentiation of the human colon adenocarcinoma cell line Caco-2. J. Cell Sci. 2005, 118:3917-3924.
2. Acquaviva F., Castaldo I., Filla A., et al. Recombinant human erythropoietin increases frataxin protein expression without increasing mRNA expression. Cerebellum 2008, 7:360-365.
3. Adamec J., Rusnak F., Owen W., et al. Irondependent self-assembly of recombinant yeast frataxin: implications for Friedreich ataxia. Am. J. Hum. Genet. 2000, 67:549-562.
4. Adinolfi S., Trifuoggi M., Politou A.S., et al. A structural approach to understanding the iron-binding properties of phylogenetically different frataxins. Hum. Mol. Genet. 2002, 11:1865-1877.
5. Adinolfi S., Iannuzzi C., Prischi F., et al. Bacterial frataxin CyaY is the gatekeeper of iron-sulfur cluster formation catalyzed by IscS. Nat. Struct. Mol. Biol. 2009, 16:390-396.
6. Al-Mahdawi S., Pinto R.M., Varshney D., et al. GAA repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neuronal and cardiac pathology. Genomics 2006, 88:580-590.
7. Al-Mahdawi S., Pinto R., Ismail O., et al. The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues. Hum. Mol. Genet. 2008, 17:735-746.
8. Aloria K., Schilke B., Andrew A., et al. Iron-induced oligomerization of yeast frataxin homologue Yfh1 is dispensable in vivo. EMBO Rep. 2004, 5:1096-1101.
9. Anderson P.R., Kirby K., Hilliker A.J., et al. RNAi-mediated suppression of the mitochondrial iron chaperone, frataxin, in Drosophila. Hum. Mol. Genet. 2005, 14:3397-3405.
10. Artuch R., Aracil A., Mas A., et al. Friedreich's ataxia: idebenone treatment in early stage patients. Neuropediatrics 2002, 33:190-193.
11. Auchère F., Santos R., Planamente S., et al. Glutathione-dependent redox status of frataxin-deficient cells in a yeast model of Friedreich's ataxia. Hum. Mol. Genet. 2008, 17:2790-2802.
12. Babady N.E., Carelle N., Wells R.D., et al. Advancements in the pathophysiology of Friedreich's Ataxia and new prospects for treatments. Mol. Genet. Metab. 2007, 92:23-35.
13. Babcock M., de Silva D., Oaks R., et al. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science 1997, 276:1709-1712.
14. Barreira A., Marques W., Sweeney M., Davis, et al. A family with Friedreich ataxia and onion-bulb formations at sural nerve biopsy. Ann. N.Y. Acad. Sci. 1999, 883:466-468.
15. Bencze K.Z., Kondapalli K.C., Cook J.D., et al. The structure and function of frataxin. Crit. Rev. Biochem. Mol. Biol. 2006, 41:269-291.
16. Bidichandani S.I., Purandare S.M., Taylor E.E., et al. Somatic sequence variation at the Friedreich ataxia locus includes complete contraction of the expanded GAA triplet repeat, significant length variation in serially passaged lymphoblasts and enhanced mutagenesis in the flanking sequence. Hum. Mol. Genet. 1999, 8:2425-2436.
17. Boddaert N., Le Quan Sang K., Rötig A., et al. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 2007, 110:401-408.
18. Boesch S., Sturm B., Hering S., et al. Friedreich's ataxia: clinical pilot trial with recombinant human erythropoietin. Ann. Neurol. 2007, 62:521-524.
19. Boesch S., Sturm B., Hering S., et al. Neurological effects of recombinant human erythropoietin in Friedreich's ataxia: a clinical pilot trial. Mov. Disord. 2008, 23:1940-1944.
20. Bradley J.L., Blake J.C., Chamberlain S., et al. Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. Hum. Mol. Genet. 2000, 9:275-282.
21. Bradley J.L., Homayoun S., Hart P.E., et al. Role of oxidative damage in Friedreich's ataxia. Neurochem. Res. 2004, 29:561-567.
22. Branda S.S., Cavadini P., Adamec J., et al. Yeast and human frataxin are processed to mature form in two sequential steps by the mitochondrial processing peptidase. J. Biol. Chem. 1999, 274:22763-22769.
23. Bulteau A.L., O'Neill H.A., Kennedy M.C., et al. Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity. Science 2004, 305:242-245.
24. Busi M.V., Maliandi M.V., Valdez H., et al. Deficiency of Arabidopsis thaliana frataxin alters activity of mitochondrial Fe-S proteins and induces oxidative stress. Plant J. 2006, 48:873-882.
25. Calabrese V., Lodi R., Tonon C., et al. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia. J. Neurol. Sci. 2005, 233:145-162.
26. Calmels N., Schmucker S., Wattenhofer-Donzé M., et al. The first cellular models based on frataxin missense mutations that reproduce spontaneously the defects associated with Friedreich ataxia. PLoS One 2009, 4:6379.
27. Campanella A., Rovelli E., Santambrogio P., et al. Mitochondrial ferritin limits oxidative damage regulating mitochondrial iron availability: hypothesis for a protective role in Friedreich ataxia. Hum. Mol. Genet. 2009, 18:1-11.
28. Campuzano V., Montermini L., Moltò M.D., et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 1996, 271:1423-1427.
29. Castaldo I., Pinelli M., Monticelli A., et al. DNA methylation in intron 1 of the frataxin gene is related to GAA repeat length and age of onset in Friedreich ataxia patients. J. Med. Genet. 2008, 45:808-812.
30. Cavadini P., Adamec J., Taroni F., et al. Two-step processing of human frataxin by mitochondrial processing peptidase. Precursor and intermediate forms are cleaved at different rates. J. Biol. Chem. 2000, 275:41469-41475.
31. Cavadini P., O'Neill H.A., Benada O., et al. Assembly and iron-binding properties of human frataxin, the protein deficient in Friedreich ataxia. Hum. Mol. Genet. 2002, 11:217-227.
32. Chamberlain S., Shaw J., Rowland A., et al. Mapping of mutation causing Friedreich's ataxia to human chromosome 9. Nature 1988, 334:248-250.
33. Chantrel-Groussard K., Geromel V., Puccio H., et al. Disabled early recruitment of antioxidant defenses in Friedreich's ataxia. Hum. Mol. Genet. 2001, 10:2061-2067.
34. Condò I., Ventura N., Malisan F., et al. In vivo maturation of human frataxin. Hum. Mol. Genet. 2007, 16:1534-1540.
35. Coppola G., Marmolino D., Lu D., et al. Functional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPARgamma pathway as a therapeutic target in Friedreich's ataxia. Hum. Mol. Genet. 2009, 18:2452-2461.
36. Cossée M., Schmitt M., Campuzano V., et al. Evolution of the Friedreich's ataxia trinucleotide repeat expansion: founder effect and premutations. Proc. Natl. Acad Sci. U. S. A. 1997, 94:7452-7457.
37. Cossée M., Dürr A., Schmitt M., et al. Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes. Ann. Neurol. 1999, 45:200-206.
38. Cossée M., Puccio H., Gansmuller A., et al. Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. Hum. Mol. Genet. 2000, 9:1219-1226.
39. De Biase I., Rasmussen A., Endres D., et al. Progressive GAA expansions in dorsal root ganglia of Friedreich's ataxia patients. Ann. Neurol. 2007, 61:55-60.
40. De Michele G., Cavalcanti F., Criscuolo C., Piane, et al. Parental gender, age at birth and expansion length influence GAA repeat intergenerational instability in the X25 gene: pedigree studies and analysis of sperm from patients with Friedreich's ataxia. Hum. Mol. Genet. 1998, 7:1901-1906.
41. Del Gaizo V., Payne R. A novel TAT-mitochondrial signal sequence fusion protein is processed, stays in mitochondria, and crosses the placenta. Mol. Ther. 2003, 7:720-730.
42. Del Gaizo V., MacKenzie J., Payne R. Targeting proteins to mitochondria using TAT. Mol. Genet. Metab. 2003, 80:170-180.
43. Delatycki M., Paris D., Gardner R., et al. Sperm DNA analysis in a Friedreich ataxia premutation carrier suggests both meiotic and mitotic expansion in the FRDA gene. J. Med. Genet. 1998, 35:713-716.
44. Delatycki M., Paris D., Gardner R., et al. Clinical and genetic study of Friedreich ataxia in an Australian population. Am. J. Med. Genet. 1999, 87:168-174.
45. Dhe-Paganon S., Shigeta R., Chi Y.I., et al. Crystal structure of human frataxin. J. Biol. Chem. 2000, 275:30753-30756.
46. Di Prospero N., Fischbeck K. Therapeutics development for triplet repeat expansion diseases. Nat. Rev. Genet. 2005, 6:756-765.
47. Di Prospero N., Baker A., Jeffries N., et al. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial. Lancet Neurol. 2007, 6:878-886.
48. Diehl B., Lee M., Reid J., et al. Atypical, perhaps under-recognized? An unusual phenotype of Friedreich ataxia. Neurogenetics 2010, 11:261-265.
49. Ditch S., Sammarco M.C., Banerjee A., et al. Progressive GAA.TTC repeat expansion in human cell lines. PLoS Genet. 2009, 5:1000704.
50. Duby G., Foury F., Ramazzotti A., et al. A non-essential function for yeast frataxin in iron-sulfur cluster assembly. Hum. Mol. Genet. 2002, 11:2635-2643.
51. Dürr A., Cossee M., Agid Y., et al. Clinical and genetic abnormalities in patients with Friedreich's ataxia. N. Engl. J. Med. 1996, 335:1169-1175.
52. Emond M., Lepage G., Vanasse M., et al. Increased levels of plasma malondialdehyde in Friedreich ataxia. Neurology 2000, 55:1752-1753.
53. Filla A., De Michele G., Cavalcanti F., et al. The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am. J. Hum. Genet. 1996, 59:554-560.
54. Foury F. Low iron concentration and aconitase deficiency in a yeast frataxin homologue deficient strain. FEBS Lett. 1999, 456:281-284.
55. Foury F., Cazzalini O. Deletion of the yeast homologue of the human gene associated with Friedreich's ataxia elicits iron accumulation in mitochondria. FEBS Lett. 1997, 411:373-377.
56. Gakh O., Adamec J., Gacy A.M., et al. Physical evidence that yeast frataxin is an iron storage protein. Biochemistry 2002, 41:6798-6804.
57. Gakh O., Park S., Liu G., et al. Mitochondrial iron detoxification is a primary function of frataxin that limits oxidative damage and preserves cell longevity. Hum. Mol. Genet. 2006, 15:467-479.
58. Gakh O., Smith D., Isaya G. Assembly of the iron-binding protein frataxin in Saccharomyces cerevisiae responds to dynamic changes in mitochondrial iron influx and stress level. J. Biol. Chem. 2008, 283:31500-31510.
59. Gellera C., Castellotti B., Mariotti C., et al. Frataxin gene point mutations in Italian Friedreich ataxia patients. Neurogenetics 2007, 8:289-299.
60. Gerber J., Mühlenhoff U., Lill R. An interaction between frataxin and Isu1/Nfs1 that is crucial for Fe/S cluster synthesis on Isu1. EMBO Rep. 2003, 4:906-911.
61. Giacchetti M., Monticelli A., De Biase I., et al. Mitochondrial DNA haplogroups influence the Friedreich's ataxia phenotype. J. Med. Genet. 2004, 41:293-295.
62. Goncalves S., Paupe V., Dassa E.P., et al. Deferiprone targets aconitase: implication for Friedreich's ataxia treatment. BMC Neurol. 2008, 8:20.
63. Gordon D., Kogan M., Knight S., et al. Distinct roles for two N-terminal cleaved domains in mitochondrial import of the yeast frataxin homolog, Yfh1p. Hum. Mol. Genet. 2001, 10:259-269.
64. Grabczyk E., Usdin K. The GAA.TTC triplet repeat expanded in Friedreich's ataxia impedes transcription elongation by T7 RNA polymerase in a length and supercoil dependent manner. Nucleic Acids Res. 2000, 28:2815-2822.
65. Grabczyk E., Mancuso M., Sammarco M. A persistent RNA*DNA hybrid formed by transcription of the Friedreich ataxia triplet repeat in live bacteria, and by T7 RNAP in vitro. Nucleic Acids Res. 2007, 35:5351-5359.
66. Greene E., Entezam A., Kumari D., et al. Ancient repeated DNA elements and the regulation of the human frataxin promoter. Genomics 2005, 85:221-230.
67. Greene E., Mahishi L., Entezam A., et al. Repeat-induced epigenetic changes in intron 1 of the frataxin gene and its consequences in Friedreich ataxia. Nucleic Acids Res. 2007, 35:3383-3390.
68. Hart P., Lodi R., Rajagopalan B., et al. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch. Neurol. 2005, 62:621-626.
69. Heidari M., Houshmand M., Hosseinkhani S., et al. A novel mitochondrial heteroplasmic C13806A point mutation associated with Iranian Friedreich's ataxia. Cell. Mol. Neurobiol. 2009, 29:225-233.
70. Heidenfelder B., Makhov A., Topal M. Hairpin formation in Friedreich's ataxia triplet repeat expansion. J. Biol. Chem. 2003, 278:2425-2431.
71. Herman D., Jenssen K., Burnett R., et al. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat. Chem. Biol. 2006, 2:551-558.
72. Herrero E., Ros J., Bellí G., et al. Redox control and oxidative stress in yeast cells. Biochim. Biophys. Acta 2008, 1780:1217-1235.
73. Houshmand M., Panahi M., Nafisi S., et al. Identification and sizing of GAA trinucleotide repeat expansion, investigation for D-loop variations and mitochondrial deletions in Iranian patients with Friedreich's ataxia. Mitochondrion 2006, 6:82-88.
74. Huang J., Dizin E., Cowan J. Mapping iron binding sites on human frataxin: implications for cluster assembly on the ISU Fe-S cluster scaffold protein. J. Biol. Inorg. Chem. 2008, 13(5):825-836.
75. Huang M., Becker E., Whitnall M., et al. Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant. Proc. Natl. Acad Sci. U. S. A. 2009, 106:16381-16386.
76. Hughes J., Brownell B., Hewer R. The peripheral sensory pathway in friedreich's ataxia. An examination by light and electron microscopy of the posterior nerve roots, posterior root ganglia, and peripheral sensory nerves in cases of friedreich's ataxia. Brain 1968, 91:803-818.
77. Irazusta V., Cabiscol E., Reverter-Branchat G., et al. Manganese is the link between frataxin and iron-sulfur deficiency in the yeast model of Friedreich ataxia. J. Biol. Chem. 2006, 281:12227-12232.
78. Jauslin M., Meier T., Smith R., et al. Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J. 2003, 17:1972-1974.
79. Jiralerspong S., Ge B., Hudson T.J., et al. Manganese superoxide dismutase induction by iron is impaired in Friedreich ataxia cells. FEBS Lett. 2001, 509:101-105.
80. Kakhlon O., Manning H., Breuer W., et al. Cell functions impaired by frataxin deficiency are restored by drugmediated iron relocation. Blood 2008, 112:5219-5227.
81. Kalinowski D., Richardson D. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol. Rev. 2005, 57:547-583.
82. Karthikeyan G., Lewis L., Resnick M. The mitochondrial protein frataxin prevents nuclear damage. Hum. Mol. Genet. 2002, 11:1351-1362.
83. Karthikeyan G., Santos J., Graziewicz M., et al. Reduction in frataxin causes progressive accumulation of mitochondrial damage. Hum. Mol. Genet. 2003, 12:3331-3342.
84. Kearney M., Orrell R., Fahey M., et al. Antioxidants and other pharmacological treatments for Friedreich ataxia. Cochrane Database Syst. Rev. 2009, (4). Art. No.: CD007791.
85. Knight S., Sepuri N., Pain D., et al. Mt-Hsp70 homolog, Ssc2p, required for maturation of yeast frataxin and mitochondrial iron homeostasis. J. Biol. Chem. 1998, 273:18389-18393.
86. Koeppen A., Michael S., Knutson M., et al. The dentate nucleus in Friedreich's ataxia: the role of ironresponsive proteins. Acta Neuropathol. 2007, 114:163-173.
87. Koeppen A., Morral J., Davis A., et al. The dorsal root ganglion in Friedreich's ataxia. Acta Neuropathol. 2009, 118:763-776.
88. Koeppen A., Morral J., McComb R., Feustel P. The neuropathology of late-onset Friedreich's ataxia. Cerebellum 2010.
89. Koutnikova H., Campuzano V., Foury F., et al. Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin. Nat. Genet. 1997, 16:345-351.
90. Koutnikova H., Campuzano V., Koenig M. Maturation of wild-type and mutated frataxin by the mitochondrial processing peptidase. Hum. Mol. Genet. 1998, 7:1485-1489.
91. Krasilnikova M., Mirkin S. Replication stalling at Friedreich's ataxia (GAA)n repeats in vivo. Mol. Cell. Biol. 2004, 24:2286-2295.
92. Ku S., Soragni E., Campau E., et al. Friedreich's ataxia induced pluripotent stem cells model intergenerational GAA.TTC triplet repeat instability. Cell Stem Cell 2010, 7:631-637.
93. Kumari D., Biacsi R., Usdin K. Repeat expansion affects both transcription initiation and elongation in friedreich ataxia cells. J. Biol. Chem. 2011, 286:4209-4215.
94. Lagedrost S., Sutton M., Cohen M., et al. Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA). Am. Heart J. 2011, 161:639-645.
95. Lamarche J., Luneau C., Lemieux B. Ultrastructural observations on spinal ganglion biopsy in Friedreich's ataxia: a preliminary report. Can. J. Neurol. Sci. 1982, 9:137-139.
96. Lamarche J.B., Shapcott D., Côté M., et al. Cardiac iron deposits in Friedreich's ataxia. Handbook of Cerebellar Diseases 1993, 453-458. Marcel Dekker, New York. R. Lechtenberg (Ed.).
97. Layer G., Ollagnier-de, Choudens S., Sanakis Y., et al. Iron-sulfur cluster biosynthesis: characterization of Escherichia coli CyaY as an iron donor for the assembly of [2Fe-2S] clusters in the scaffold IscU. J. Biol. Chem. 2006, 281:16256-16263.
98. Le Proust E., Pearson C., Sinden R., et al. Unexpected formation of parallel duplex in GAA and TTC trinucleotide repeats of Friedreich's ataxia. J. Mol. Biol. 2000, 302:1063-1080.
99. Lesuisse E., Santos R., Matzanke B., et al. Iron use for haeme synthesis is under control of the yeast frataxin homologue (Yfh1). Hum. Mol. Genet. 2003, 12:879-889.
100. Li D., Ohshima K., Jiralerspong S., et al. Knock-out of the cyaY gene in Escherichia coli does not affect cellular iron content and sensitivity to oxidants. FEBS Lett. 1999, 456:13-16.
101. Li K., Besse E., Ha D., et al. Iron-dependent regulation of frataxin expression: implications for treatment of Friedreich ataxia. Hum. Mol. Genet. 2008, 17:2265-2273.
102. Li H., Gakh O., Smith D., et al. Oligomeric yeast frataxin drives assembly of core machinery for mitochondrial iron-sulfur cluster synthesis. J. Biol. Chem. 2009, 284:21971-21980.
103. Li K., Singh A., Crooks D.R., Dai, et al. Expression of human frataxin is regulated by transcription factors SRF and TFAP2. PLoS One 2010, 5:12286.
104. Liu J., Verma P., Evans-Galea M., et al. Generation of Induced Pluripotent Stem Cell Lines from Friedreich Ataxia Patients. Stem Cell Rev. 2010, 2010 Dec 22 (Electronic publication ahead of print).
105. Llorens J., Navarro J., Martínez-Sebastián M., et al. Causative role of oxidative stress in a Drosophila model of Friedreich ataxia. FASEB J. 2007, 21:333-344.
106. Long S., Jirku M., Mach J., et al. Ancestral roles of eukaryotic frataxin: mitochondrial frataxin function and heterologous expression of hydrogenosomal Trichomonas homologues in trypanosomes. Mol. Microbiol. 2008, 69:94-109.
107. Lu C., Schoenfeld R., Shan Y., et al. Frataxin deficiency induces Schwann cell inflammation and death. Biochim. Biophys. Acta 2009, 1792:1052-1061.
108. Lynch D., Perlman S., Meier T. A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia. Arch. Neurol. 2010, 67:941-947.
109. Mariotti C., Solari A., Torta D., et al. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 2003, 60(10):1676-1679.
110. Marmolino D., Acquaviva F., Pinelli M., et al. PPAR-gamma agonist azelaoyl PAF increases frataxin protein and mRNA expression. New implications for the Friedreich's ataxia therapy. Cerebellum 2009, 8:98-103.
111. Marmolino D., Manto M., Acquaviva F., et al. PGC-1alpha down-regulation affects the antioxidant response in Friedreich's ataxia. PLoS One 2010, 7:5-10025.
112. Mascalchi M., Salvi F., Piacentini S., et al. Friedreich's ataxia: MR findings involving the cervical portion of the spinal cord. AJR. Am. J. Roentgenol. 1994, 163:187-191.
113. McCormack M., Guttmann R., Schumann M., et al. Frataxin point mutations in two patients with Friedreich's ataxia and unusual clinical features. J. Neurol. Neurosurg. Psychiatry 2000, 68:661-664.
114. Meier T., Buyse G. Idebenone: an emerging therapy for Friedreich ataxia. J. Neurol. 2009, 256:25-30.
115. Michael S., Petrocine S., Qian J., et al. Iron and iron-responsive proteins in the cardiomyopathy of Friedreich's ataxia. Cerebellum 2006, 5:257-267.
116. Montermini L., Andermann E., Labuda M., et al. The Friedreich ataxia GAA triplet repeat: premutation and normal alleles. Hum. Mol. Genet. 1997, 6:1261-1266.
117. Montermini L., Richter A., Morgan K., et al. Phenotypic variability in Friedreich ataxia: role of the associated GAA triplet repeat expansion. Ann. Neurol. 1997, 41:675-682.
118. Morral J., Davis A., Qian J., et al. Pathology and pathogenesis of sensory neuropathy in Friedreich's ataxia. Acta Neuropathol. 2010, 120:97-108.
119. Muckenthaler M., Galy B., Hentze M. Systemic iron homeostasis and the ironresponsive element/iron-regulatory protein (IRE/IRP) regulatory network. Annu. Rev. Nutr. 2008, 28:197-213.
120. Mühlenhoff U., Richhardt N., Ristow M., et al. The yeast frataxin homolog Yfh1p plays a specific role in the maturation of cellular Fe/S proteins. Hum. Mol. Genet. 2002, 11:2025-2036.
121. Musco G., Stier G., Kolmerer B., et al. Towards a structural understanding of Friedreich's ataxia: the solution structure of frataxin. Structure 2000, 8:695-707.
122. Myers L., Lynch D., Farmer J., et al. Urinary isoprostanes in Friedreich ataxia: lack of correlation with disease features. Mov. Disord. 2008, 23:1920-1922.
123. Napoli E., Taroni F., Cortopassi G. Frataxin, iron-sulfur clusters, heme, ROS, and aging. Antioxid. Redox Signal. 2006, 8:506-516.
124. Oktay Y., Dioum E., Matsuzaki S., et al. Hypoxia-inducible factor 2α regulates expression of the mitochondrial aconitase chaperone protein frataxin. J. Biol. Chem. 2007, 282:11750-11756.
125. O'Neill H.A., Gakh O., Isaya G. Supramolecular assemblies of human frataxin are formed via subunit-subunit interactions mediated by a non-conserved amino-terminal region. J. Mol. Biol. 2005, 345:433-439.
126. Ouvrier R., McLeod J., Conchin T. Friedreich's ataxia. Early detection and progression of peripheral nerve abnormalities. J. Neurol. Sci. 1982, 55:137-145.
127. Pandolfo M. Iron metabolism and mitochondrial abnormalities in Friedreich ataxia. Blood Cells Mol. Dis. 2002, 29:536-547.
128. Pandolfo M. Friedreich ataxia: the clinical picture. J. Neurol. 2009, 256:3-8.
129. Park S., Gakh O., Mooney S., et al. The ferroxidase activity of yeast frataxin. J. Biol. Chem. 2002, 277:38589-38595.
130. Park S., Gakh O., O'Neill H., et al. Yeast frataxin sequentially chaperones and stores iron by coupling protein assembly with iron oxidation. J. Biol. Chem. 2003, 278:31340-31351.
131. Paupe V., Dassa E., Goncalves S., et al. Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia. PLoS One 2009, 4:e4253.
132. Philpott C., Protchenko O. Response to iron deprivation in Saccharomyces cerevisiae. Eukaryot. Cell 2008, 7:20-27.
133. Pianese L., Tammaro A., Turano M., et al. Identification of a novel transcript of X25, the human gene involved in Friedreich ataxia. Neurosci. Lett. 2002, 320:137-140.
134. Piemonte F., Pastore A., Tozzi G., et al. Glutathione in blood of patients with Friedreich's ataxia. Eur. J. Clin. Invest. 2001, 31:1007-1011.
135. Pollard L., Sharma R., Gomez M., et al. Replication-mediated instability of the GAA triplet repeat mutation in Friedreich ataxia. Nucleic Acids Res. 2004, 32:5962-5971.
136. Puccio H. Multicellular models of Friedreich ataxia. J. Neurol. 2009, 256:18-24.
137. Puccio H., Simon D., Cossée M., et al. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat. Genet. 2001, 27:181-186.
138. Radisky D., Babcock M., Kaplan J. The yeast frataxin homologue mediates mitochondrial iron efflux. Evidence for a mitochondrial iron cycle. J. Biol. Chem. 1999, 274:4497-4499.
139. Rai M., Soragni E., Jenssen K., et al. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS One 2008, 3:1958.
140. Rai M., Soragni E., Chou C.J., et al. Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model. PLoS One 2010, 21:5-8825.
141. Richardson D. Friedreich's ataxia: iron chelators that target the mitochondrion as a therapeutic strategy?. Expert Opin. Investig. Drugs 2003, 12:235-245.
142. Richardson D., Mouralian C., Ponka P., et al. Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron. Biochim. Biophys. Acta 2001, 1536:133-140.
143. Riessland M., Brichta L., Hahnen E., et al. The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells. Hum. Genet. 2006, 120:101-110.
144. Rindler P., Clark R., Pollard L., et al. Replication in mammalian cells recapitulates the locus-specific differences in somatic instability of genomic GAA triplet-repeats. Nucleic Acids Res. 2006, 34:6352-6361.
145. Rizzuto N., Monaco S., Moretto G., et al. Friedreich's ataxia. A light- and electron microscopic study of peripheral nerve biopsies. Acta Neuropathol. Suppl. 1981, 7:344-347.
146. Rötig A., de Lonlay P., Chretien D., et al. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat. Genet. 1997, 17:215-217.
147. Rouault T., Tong W. Iron-sulfur cluster biogenesis and human disease. Trends Genet. 2008, 24:398-407.
148. Rustin P., von Kleist-Retzow J.C., Chantrel-Groussard K., et al. Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Lancet 1999, 354:477-479.
149. Saccà F., Piro R., De Michele G., et al. Epoetin alfa increases frataxin production in Friedreich's ataxia without affecting hematocrit. Mov. Disord. 2011, 26:739-742.
150. Said G., Marion M., Selva J., et al. Hypotrophic and dying-back nerve fibers in Friedreich's ataxia. Neurology 1986, 36:1292-1299.
151. Saint-Georges Y., Garcia M., Delaveau T., et al. Yeast mitochondrial biogenesis: a role for the PUF RNA-binding protein Puf3p in mRNA localization. PLoS One 2008, 3:2293.
152. Sakamoto N., Chastain P., Parniewski P., et al. Sticky DNA: self-association properties of long GAA.TTC repeats in R.R.Y triplex structures from Friedreich's ataxia. Mol. Cell 1999, 3:465-475.
153. Sakamoto N., Ohshima K., Montermini L., et al. Sticky DNA, a self associated complex formed at long GAA.TTC repeats in intron 1 of the frataxin gene, inhibits transcription. J. Biol. Chem. 2001, 276:27171-27177.
154. Sanchez-Casis G., Cote M., Barbeau A. Pathology of the heart in Friedreich's ataxia: review of the literature and report of one case. Can. J. Neurol. Sci. 1976, 3:349-354.
155. Santoro L., De Michele G., Perretti A., et al. Relation between trinucleotide GAA repeat length and sensory neuropathy in Friedreich's ataxia. J. Neurol. Neurosurg. Psychiatry 1999, 66:93-96.
156. Santos M., Ohshima K., Pandolfo M. Frataxin deficiency enhances apoptosis in cells differentiating into neuroectoderm. Hum. Mol. Genet. 2001, 10:1935-1944.
157. Santos R., Buisson N., Knight S.A., et al. Candida albicans lacking the frataxin homologue: a relevant yeast model for studying the role of frataxin. Mol. Microbiol. 2004, 54:507-519.
158. Sarsero J., Li L., Wardan H., et al. Upregulation of expression from the FRDA genomic locus for the therapy of Friedreich ataxia. J. Gene Med. 2003, 5:72-81.
159. Schmucker S., Puccio H. Understanding the molecular mechanisms of Friedreich's ataxia to develop therapeutic approaches. Hum. Mol. Genet. 2010, 19:103-110.
160. Schmucker S., Argentini M., Carelle-Calmels N., et al. The in vivo mitochondrial two-step maturation of human frataxin. Hum. Mol. Genet. 2008, 17:3521-3531.
161. Schmucker S., Martelli A., Colin F., et al. Mammalian frataxin: an essential function for cellular viability through an interaction with a preformed ISCU/NFS1/ISD11 iron-sulfur assembly complex. PLoS One 2011, 6:16199.
162. Schoenle E., Boltshauser E., Baekkeskov S., et al. Preclinical and manifest diabetes mellitus in young patients with Friedreich's ataxia: no evidence of immune process behind the islet cell destruction. Diabetologia 1989, 32:378-381.
163. Schöls L., Amoiridis G., Przuntek H., et al. Friedreich's ataxia. Revision of the phenotype according to molecular genetics. Brain 1997, 120:2131-2140.
164. Schulz J., Dehmer T., Schöls L., et al. Oxidative stress in patients with Friedreich ataxia. Neurology 2000, 55:1719-1721.
165. Seguin A., Bayot A., Dancis A., et al. Overexpression of the yeast frataxin homolog (Yfh1): contrasting effects on iron-sulfur cluster assembly, heme synthesis and resistance to oxidative stress. Mitochondrion 2009, 9:130-138.
166. Seznec H., Simon D., Bouton C., et al. Friedreich ataxia: the oxidative stress paradox. Hum. Mol. Genet. 2004, 14:463-474.
167. Sharma R., Bhatti S., Gomez M., et al. The GAA triplet-repeat sequence in Friedreich ataxia shows a high level of somatic instability in vivo, with a significant predilection for large contractions. Hum. Mol. Genet. 2002, 11:2175-2187.
168. Sharma R., De Biase I., Gómez M., et al. Friedreich ataxia in carriers of unstable borderline GAA triplet-repeat alleles. Ann. Neurol. 2004, 56:898-901.
169. Simon D., Seznec H., Gansmuller A., et al. Friedreich ataxia mouse models with progressive cerebellar and sensory ataxia reveal autophagic neurodegeneration in dorsal root ganglia. J. Neurosci. 2004, 24:1987-1995.
170. Sohn Y., Breuer W., Munnich A., et al. Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications. Blood 2008, 111:1690-1699.
171. Sturm B., Stupphann D., Kaun C., et al. Recombinant human erythropoietin: effects on frataxin expression in vitro. Eur. J. Clin. Invest. 2005, 35:711-717.
172. Sturm B., Helminger M., Steinkellner H., et al. Carbamylated erythropoietin increases frataxin independent from the erythropoietin receptor. Eur. J. Clin. Invest. 2010, 40:561-565.
173. Tan G., Chen L., Lonnerdal B., et al. Frataxin expression rescues mitochondrial dysfunctions in FRDA cells. Hum. Mol. Genet. 2001, 10:2099-2107.
174. Vázquez-Manrique R., González-Cabo P., Ros S., et al. Reduction of Caenorhabditis elegans frataxin increases sensitivity to oxidative stress, reduces lifespan, and causes lethality in a mitochondrial complex II mutant. FASEB J. 2006, 20:172-174.
175. Veatch J., McMurray M., Nelson Z., et al. Mitochondrial dysfunction leads to nuclear genome instability via an iron-sulfur cluster defect. Cell 2009, 137:1247-1258.
176. Voisine C., Schilke B., Ohlson M., et al. Role of the mitochondrial Hsp70s, Ssc1 and Ssq1, in the maturation of Yfh1. Mol. Cell. Biol. 2000, 20:3677-3684.
177. Waldvogel D., van Gelderen P., Hallett M. Increased iron in the dentate nucleus of patients with Friedrich's ataxia. Ann. Neurol. 1999, 46:123-125.
178. Wang T., Craig E. Binding of yeast frataxin to the scaffold for Fe-S cluster biogenesis, Isu. J. Biol. Chem. 2008, 283:12674-12679.
179. Wells R.D. DNA triplexes and Friedreich ataxia. FASEB J. 2008, 22:1625-1634.
180. Wilson R. Iron dysregulation in Friedreich ataxia. Semin. Pediatr. Neurol. 2006, 13:166-175.
181. Wilson R., Roof D. Respiratory deficiency due to loss of mitochondrial DNA in yeast lacking the frataxin homologue. Nat. Genet. 1997, 16:352-357.
182. Wilson R., Lynch D., Fischbeck K. Normal serum iron and ferritin concentrations in patients with Friedreich's ataxia. Ann. Neurol. 1998, 44:132-134.
183. Wilson R., Lynch D., Farmer J., et al. Increased serum transferrin receptor concentrations in Friedreich ataxia. Ann. Neurol. 2000, 47:659-661.
184. Winterbourn C., Hampton M. Thiol chemistry and specificity in redox signaling. Free Radic. Biol. Med. 2008, 145:549-561.
185. Wong A., Yang J., Cavadini P., et al. The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum. Mol. Genet. 1999, 8:425-430.
186. Wu Z., Puigserver P., Andersson U., et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 1999, 98:115-124.
187. Ye H., Rouault T.A. Human iron-sulfur cluster assembly, cellular iron homeostasis, and disease. Biochemistry 2010, 49:4945-4956.
188. Yoon T., Cowan J. Iron-sulfur cluster biosynthesis. Characterization of frataxin as an iron donor for assembly of [2Fe-2S] clusters in ISU-type proteins. J. Am. Chem. Soc. 2003, 125:6078-6084.
189. Yoon T., Cowan J. Frataxin-mediated iron delivery to ferrochelatase in the final step of heme biosynthesis. J. Biol. Chem. 2004, 279:25943-25946.
190. Zouari M., Feki M., Ben Hamida C., et al. Electrophysiology and nerve biopsy: comparative study in Friedreich's ataxia and Friedreich's ataxia phenotype with vitamin E deficiency. Neuromuscul. Disord. 1998, 8:416-425.
191. Zühlke C., Dalski A., Habeck M., et al. Extension of the mutation spectrum in Friedreich's ataxia: detection of an exon deletion and novel missense mutations. Eur. J. Hum. Genet. 2004, 12:979-982.